Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 14, 2002. The report discloses specific corporate actions regarding share repurchases and changes in directors' share interests.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on the following transactional data:
- Share Repurchase Price: 1248.97p per share.
- Director Share Purchase Price: £12.10 per share.
Material Changes and Transactions
Share Repurchase Program
In accordance with shareholder authority granted at the Annual General Meeting on May 20, 2002, the company purchased 800,000 ordinary shares for cancellation on November 13, 2002.
Directors' Interests
Mr. J.D. Coombe acquired a total of 22 ordinary shares on November 11, 2002, through the Company's ShareReward Plan:
- 11 shares acquired via the partnership element (personal contribution).
- 11 shares acquired via the matching element (Company contribution).
Guidance, Outlook, and Risks
The filing text does not provide management commentary, future guidance, outlook, risk factors, contingencies, or unusual items beyond the disclosed transactions.
Investor Verification Checklist
- Verify the total number of shares repurchased under the May 2002 authorization to date.
- Confirm the impact of the 800,000 share cancellation on the company's total share count.
- Review the full terms of the ShareReward Plan to understand the matching contribution structure.